Drawing for NIVOSET

USPTO serial 98128462

NIVOSET

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
FRIZALONE, SARAH O
Law office
TMO LAW OFFICE 112

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with NIVOSET?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark J. Liss

Mark J. Liss LEYDIG, VOIT & MAYER, LTD.TWO PRUDENTIAL PLAZA, 180 N. STETSON AVESUITE 4900CHICAGO, IL 60601

Goods and services

ClassDescriptionStatusFirst use
005Chemico-pharmaceutical preparations for treating glabellar lines, forehead wrinkles, lateral canthal line, prostate disorder, excessive eye blinking, and pelvic pain; muscle relaxants; anaesthetics; pharmaceutical agents affecting peripheral nervous system; bacterial poisons; pharmacological preparations for skin care, namely, pharmaceutical preparations for skin care; pharmaceutical preparations acting on the central nervous system; biological preparations for medical purposes being bacterial and bacteriological preparations; implantable medicines being medicinal infusions, injectable gels, injectable pharmaceuticals for use in the treatment of neurological disorders and muscle dystonia; pharmaceuticals containing botulinum toxin for medical use for use in the treatment of glabellar lines, forehead wrinkles, lateral canthal line, prostate disorder, excessive eye blinking, and pelvic painACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Aug 18, 2025MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Aug 18, 2025ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
May 1, 2025GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
May 1, 2025GNSIINQUIRY TO SUSPENSION E-MAILED—
May 1, 2025CNSISUSPENSION INQUIRY WRITTEN—
May 1, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Oct 31, 2024GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 31, 2024GNSLLETTER OF SUSPENSION E-MAILED—
Oct 31, 2024CNSLSUSPENSION LETTER WRITTEN—
Oct 10, 2024ALIEASSIGNED TO LIE—
Oct 9, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 9, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 25, 2024ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 3, 2024GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Apr 3, 2024GNSIINQUIRY TO SUSPENSION E-MAILED—
Apr 3, 2024CNSISUSPENSION INQUIRY WRITTEN—
Mar 18, 2024RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Sep 18, 2023GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Sep 18, 2023GNSLLETTER OF SUSPENSION E-MAILED—
Sep 18, 2023CNSLSUSPENSION LETTER WRITTEN—
Sep 14, 2023DOCKASSIGNED TO EXAMINER—
Sep 11, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 15, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance